Patents Examined by Kahsay Habte
  • Patent number: 12264169
    Abstract: The present invention relates to compounds and methods useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.
    Type: Grant
    Filed: July 11, 2023
    Date of Patent: April 1, 2025
    Assignee: Tetra Discovery Partners
    Inventors: Mark E. Gurney, Timothy J. Hagen, Xuesheng Mo, A. Samuel Vellekoop, Donna L. Romero, Robert Campbell, Joel R. Walker, Lei Zhu
  • Patent number: 12264149
    Abstract: Disclosed herein are compounds and methods of treating diseases and/or conditions associated with FGFR inhibition.
    Type: Grant
    Filed: December 30, 2021
    Date of Patent: April 1, 2025
    Assignee: TYRA BIOSCIENCES, INC.
    Inventors: Robert L. Hudkins, Daniel C. Bensen
  • Patent number: 12264165
    Abstract: Described herein is a process for the preparation of a compound of Formula I, wherein R1 and R2 each have the meanings provided in the description. Also described is a process for the preparation of pharmaceutically-active compounds including the process for the preparation of compounds of Formula I.
    Type: Grant
    Filed: May 19, 2023
    Date of Patent: April 1, 2025
    Assignee: Kancera AB
    Inventors: Jan Vågberg, Styrbjörn Byström
  • Patent number: 12264153
    Abstract: The present disclosure provides compounds which are useful for a number of catalytic transformations of organic molecules, non-limiting examples including dehydrogenation of alkanes. The present disclosure further relates to methods of preparing the compounds of the present disclosure.
    Type: Grant
    Filed: April 22, 2024
    Date of Patent: April 1, 2025
    Assignee: Rutgers, The State University of New Jersey
    Inventors: Alan S. Goldman, Thomas R. Dugan
  • Patent number: 12264152
    Abstract: The present disclosure provides CDK9 inhibitors. Also provided are methods of treating a disease or a disorder comprising administering to a subject in need of treatment one of the CDK9 inhibitors disclosed herein. In some embodiments, the disease or disorder to be treated is cancer. In some embodiments, the disease or disorder is liver cancer.
    Type: Grant
    Filed: January 17, 2023
    Date of Patent: April 1, 2025
    Assignee: Algen Biotechnologies, Inc.
    Inventors: Andrei W. Konradi, Chun-Hao Huang, Ko-Chuan Lee
  • Patent number: 12264154
    Abstract: Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3, R4, R6, R7, R8 and n are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
    Type: Grant
    Filed: February 1, 2024
    Date of Patent: April 1, 2025
    Assignee: Tango Therapeutics, Inc.
    Inventors: Kevin M. Cottrell, John P. Maxwell
  • Patent number: 12258338
    Abstract: The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts, solvates, hydrates, tautomers or stereoisomers thereof, wherein R1, R2, R2a, R3, Ra2, Ra4, Ra5, Ra6, Ra7, X1, X1a, A1 and A2 have the meaning as indicated in the description and claims. The invention further relates to pharmaceutical compositions comprising said compounds, their use as medicament and in a method for treating and preventing of one or more diseases or disorders associated with integrated stress response.
    Type: Grant
    Filed: April 22, 2020
    Date of Patent: March 25, 2025
    Assignee: Evotec International GmbH
    Inventors: Holly Atton, Christopher John Brown, James Lindsay Carr, Serge Convers-Reignier, Michael Corr, Marissa Flower, Christopher Francis Palmer, Irena Reboule, Mohamad Sabbah, Scott Sadler, Jonathan Shine, Daryl Simon Walter
  • Patent number: 12258423
    Abstract: The present invention provides stapled polypeptides of the Formulae (I) and (VI): and salts thereof; wherein the groups ; R1a, R1b, R1c, R2a, R3a, R2b, R3b, R4a, R4b, RA, RZ, L1a, L1b, L2, L3, XAA, v, w, p, m, s, n, t, and q are as defined herein. The present invention further provides methods of preparing the inventive stapled polypeptides from unstapled polypeptide precursors. The present invention further provides pharmaceutical compositions comprising a stapled polypeptide of Formula (I) or (VI), and methods of using the stapled peptides. The present invention also provides modifications of the staples post ring closing metathesis.
    Type: Grant
    Filed: November 17, 2020
    Date of Patent: March 25, 2025
    Assignee: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Gregory L. Verdine, Gerard Hilinski
  • Patent number: 12240831
    Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-?.
    Type: Grant
    Filed: September 1, 2023
    Date of Patent: March 4, 2025
    Assignee: EDGEWISE THERAPEUTICS, INC.
    Inventors: Kevin Hunt, Kevin Koch, Alan Russell, Stephen Schlachter, Paul Winship, Chris Steele
  • Patent number: 12239640
    Abstract: The invention discloses use of miloxacin in the preparation of medicines for treating and/or preventing diseases with T-type calcium channel as a therapeutic target. The invention discloses new use of miloxacin, which provides a new theoretical and technical support for developing medicines for treating and/or preventing diseases with T-type calcium channel as a therapeutic target, thus having a broad prospect of application in the field of clinical treatment.
    Type: Grant
    Filed: February 20, 2021
    Date of Patent: March 4, 2025
    Assignee: SOOCHOW UNIVERSITY
    Inventors: Jin Tao, Yuan Zhang, Yufang Sun, Xinghong Jiang
  • Patent number: 12234235
    Abstract: The present invention discloses salts of a Compound 1: useful in the prophylaxis and/or treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving degradation and/or disruption of cartilage homeostasis, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons.
    Type: Grant
    Filed: April 25, 2023
    Date of Patent: February 25, 2025
    Assignee: ALFASIGMA S.P.A.
    Inventors: Nicolas Luc Sabourault, Carla De Faveri, Ahmad Sheikh, Piet Wigerinck
  • Patent number: 12235275
    Abstract: The post-translational modification (PTM) and signaling molecule poly(ADP-ribose) (PAR) has an impact on diverse biological processes. PTM is regulated by a series of ADP-ribosyl glycohydrolases (PARG enzymes) that cleave polymers and/or liberate monomers from their protein targets. Disclosed herein is a substrate for monitoring PARG activity, TFMU-ADPr, which directly reports on total PAR hydrolase activity via release of a fluorophore; this substrate has excellent reactivity, generality, stability, and usability. A second substrate, TFMU-IDPr, selectively reports on PARG activity only from the enzyme ARH3. Use of these probes in whole-cell lysate experiments has revealed a mechanism by which ARH3 is inhibited by cholera toxin. TFMU-ADPr and TFMU-IDPr are versatile tools for assessing small-molecule inhibitors in vitro and probing the regulation of ADP-ribosyl catabolic enzymes.
    Type: Grant
    Filed: September 9, 2019
    Date of Patent: February 25, 2025
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Paul J. Hergenrother, Bryon S. Drown
  • Patent number: 12227499
    Abstract: Disclosed are fused imidazole derivatives, preparation methods therefor and medical uses thereof. Specifically, the present disclosure relates to a fused imidazole derivative as shown in general formula (IM), a preparation method therefor, a pharmaceutical composition containing the derivative, and the use of same as a therapeutic agent, in particular the use thereof as a GLP-1 receptor agonist, and the use thereof in the preparation of drugs for the treatment and/or prevention of diabetes.
    Type: Grant
    Filed: September 1, 2021
    Date of Patent: February 18, 2025
    Assignee: Jiangsu Hengrui Pharmaceuticals Co., Ltd.
    Inventors: Fanglong Yang, Ling Zhang, Liangliang Zheng, Feng He, Weikang Tao
  • Patent number: 12227502
    Abstract: The present invention relates to substituted pyrrolopyridinones and substituted pyrazolopyridinones which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: May 31, 2023
    Date of Patent: February 18, 2025
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Andrew P. Combs, Thomas P. Maduskuie, Jr., Nikoo Falahatpisheh
  • Patent number: 12220406
    Abstract: Disclosed herein are pharmaceutical compositions to treat or prevent obesity, excess or overweight conditions, and metabolic syndrome comprising an effective amount of one or more mTOR inhibitors and optionally an effective amount of one or more thyroid hormones and/or an effective amount of one or more cholesterol-lowering agents. Further disclosed herein are methods of treating or preventing obesity, excess or overweight conditions, and metabolic syndrome comprising administering an effective amount of a pharmaceutical composition comprising one or more mTOR inhibitors and optionally an effective amount of one or more thyroid hormones and/or an effective amount of one or more cholesterol-lowering agents.
    Type: Grant
    Filed: June 10, 2021
    Date of Patent: February 11, 2025
    Inventor: Thomas Winston
  • Patent number: 12215101
    Abstract: The present invention is directed to pro drugs of 2-methyl-N-((5-methyl-1,3,4-thiadiazol-2-yl)methyl)-6-(((1S,2S)-2-(5-methylpyridin-2-yl)cyclopropyl)methoxy)pyrimidin-4-amine which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
    Type: Grant
    Filed: December 13, 2023
    Date of Patent: February 4, 2025
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Sachin Mittal, Jason W. Skudlarek, Izzat T. Raheem
  • Patent number: 12215103
    Abstract: Disclosed are fused imidazole derivatives, preparation methods therefor and medical uses thereof. Specifically, the present disclosure relates to a fused imidazole derivative as shown in general formula (IM), a preparation method therefor, a pharmaceutical composition containing the derivative, and the use of same as a therapeutic agent, in particular the use thereof as a GLP-1 receptor agonist, and the use thereof in the preparation of drugs for the treatment and/or prevention of diabetes.
    Type: Grant
    Filed: March 21, 2024
    Date of Patent: February 4, 2025
    Assignee: Jiangsu Hengrui Pharmaceuticals Co., Ltd.
    Inventors: Fanglong Yang, Ling Zhang, Liangliang Zheng, Feng He, Weikang Tao
  • Patent number: 12209081
    Abstract: The invention relates to compounds that are useful for the prevention or treatment of TRPM3 mediated disorders, more in particular disorders selected from pain and inflammatory hypersensitivity. The invention also relates to a method for the prevention or treatment of said TRPM3 mediated disorders.
    Type: Grant
    Filed: May 12, 2024
    Date of Patent: January 28, 2025
    Assignee: Katholieke Universiteit Leuven
    Inventors: Patrick Chaltin, Arnaud Marchand, Jean-Christophe Vanherck, Thomas Voets, Joris Vriens, Melanie Reich, André Welbers
  • Patent number: 12209102
    Abstract: The present disclosure provides compounds and pharmaceutically acceptable salts thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, the subject compositions and methods are useful for reducing signaling output of oncogenic proteins.
    Type: Grant
    Filed: May 17, 2024
    Date of Patent: January 28, 2025
    Assignee: Kumquat Biosciences Inc.
    Inventors: Pingda Ren, Liansheng Li, Baogen Wu, Xiaoming Li, Zhiyong Chen, Siling Zhao, Yi Liu, Xiuwen Zhu
  • Patent number: 12202817
    Abstract: The subject matter described herein is directed to ferroportin inhibitor compounds of Formula I or I? and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis, and also kidney injuries.
    Type: Grant
    Filed: June 15, 2023
    Date of Patent: January 21, 2025
    Assignee: Global Blood Therapeutics, Inc.
    Inventors: Qing Xu, Carsten Alt, Zhe Li, Shahul Nilar, Peter Michael Rademacher, Calvin Wesley Yee